692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). - Cattrini, C.; Lozano Mejorada, R.; Conteduca, V.; Ruiz-Vico, M.; Lolkema, M.P.; Lorente, D.; Sandhu, S.; Romero Laorden, N.; Loriot, Y.; Azad, A.A.; Costa, L.; Vinceneux, A.; et al. (Annals of Oncology, 2020)